OM336 in Autoimmune Cytopenias
Key facts
- Where
- Brisbane, Canberra, and Sydney, AustraliaSee the 3 sites
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07083960, who can take part
Where in Australia
- Icon Cancer Center South BrisbaneBrisbane, AustraliaContact: Clinical Research CoordinatorTaking people
- The Canberra HospitalCanberra, AustraliaContact: Clinical Research CoordinatorTaking people
- Liverpool HospitalSydney, AustraliaContact: Clinical Research CoordinatorTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Lakefront Biotherapeutics West LLC
- Trial code
- NCT07083960
- Record updated
- 3 September 2026
- Original description
An early-phase clinical trial evaluating the safety, tolerability, and pharmacokinetics of subcutaneously dosed OM336 in adult participants with autoimmune cytopenias.Read full original descriptionShow less
An Open-Label, Phase 1b, Multiple Ascending Dose Study of OM336 in Participants With Active Autoimmune Cytopenias
An early-phase clinical trial evaluating the safety, tolerability, and pharmacokinetics of subcutaneously dosed OM336 in adult participants with autoimmune cytopenias.
Inclusion: Active autoimmune cytopenia; Relapsed/refractory after ≥1 prior treatment; Body weight ≥ 55 kg; Willing to comply with and study requirements and procedures.
Exclusion: Previous treatment with a BCMA-targeted therapy; Major surgery or splenectomy within 3 months of screening or planned during the study; Clinically significant infection within 3 months of screening; Pregnant or breastfeeding.